Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration 21 CFR Parts 510, 516, 520, 522, 524, 529, 556, and 558
[Docket No. FDA-2024-N-0002]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Final rule; technical amendments.
 SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during April, May, and June 2024. The animal drug regulations are also being amended to improve their accuracy and readability.
 DATES: This rule is effective October 28, 2024.
 FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, 
                        *George.Haibel@fda.hhs.gov*.


SUPPLEMENTARY INFORMATION: I. Approvals FDA is amending the animal drug regulations to reflect approval actions for NADAs, ANADAs, and CNADAs during April, May, and June 2024, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOIA Summaries) under the Freedom of Information Act (FOIA). These documents, along with marketing exclusivity and patent information, may be obtained at Animal Drugs @FDA: 
                    *https://animaldrugsatfda.fda.gov/​adafda/​views/​#/​search.*( print page 85424) Table 1—Original and Supplemental NADAs, ANADAs, and CNADAs Approved During April, May, and June 2024 Requiring Evidence of Safety and/or Effectiveness
Date of approval
File No.
Sponsor
                             (drug labeler code)
Product name
Effect of the action
21 CFR
                             sectionApril 5, 2024
141-043
Zoetis Inc, 333 Portage St., Kalamazoo, MI 49007 (054771)
SYNOVEX CHOICE (trenbolone acetate and estradiol benzoate) and SYNOVEX PRIMER (trenbolone acetate and estradiol benzoate)
Supplemental approval for increased rate of weight gain in growing beef steers and heifers in a dry lot
522.2478April 9, 2024
141-550
Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140 (058198)
PRADALEX (pradofloxacin injection)
Original approval for treatment of bovine respiratory disease and swine respiratory disease
522.1860
                             556.530April 10, 2024
200-777
Felix Pharmaceuticals PVT Ltd., 25-28 North Wall Quay, Dublin 1, Ireland (086101)
Carprofen Injectable Solution
Original approval as a generic copy of NADA 141-199
522.304April 25, 2024
200-728
Cronus Pharma Specialties India Private Ltd., Plot No. 9(B), Survey No. 99/1, GMR Hyderabad Aviation SEZ Ltd., Mamidipalle Village, Balapur Mandal, Shamshabad, Rangareddy, Hyderabad, Telangana, 500108, India (069043)
PIMOMEDIN (pimobendan) Tablets
Original approval as a generic copy of NADA 141-033
520.1780April 26, 2024
141-582
Warburton Technology Ltd., 36 Fitzwilliam Square, Dublin, Dublin, D02HX82, Ireland (066679)
MULTIMIN 90 (zinc, copper, manganese, and selenium injection)
Original approval as a supplemental source of zinc, copper, manganese, and selenium in cattle
522.2694May 8, 2024
200-780
Aurora Pharmaceutical, Inc., 1196 Highway 3 South, Northfield, MN 55057-3009 (051072)
COCCIAID (amprolium) for Calves
Original approval as a generic copy of NADA 013-149
520.100May 9, 2024
200-782
Cronus Pharma Specialties India Private Ltd., Plot No. 9(B), Survey No. 99/1, GMR Hyderabad Aviation SEZ Ltd., Mamidipalle Village, Balapur Mandal, Shamshabad, Rangareddy, Hyderabad, Telangana, 500108, India (069043)
ENROPRO Silver Otic (enrofloxacin/silver sulfadiazine) Otic Emulsion
Original approval as a generic copy of NADA 141-176
524.802May 10, 2024
141-577
Vetoquinol USA, Inc., 4250 N Sylvania Ave., Fort Worth, TX 76137 (017030)
UPCARD-CA1 (torsemide oral solution)
Conditional approval as concurrent therapy with pimobendan, spironolactone, and an angiotensin converting enzyme (ACE) inhibitor for the management of pulmonary edema in dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD)
516.2475May 16, 2024
200-781
Cronus Pharma Specialties India Private Ltd., Plot No. 9(B), Survey No. 99/1, GMR Hyderabad Aviation SEZ Ltd., Mamidipalle Village, Balapur Mandal, Shamshabad, Rangareddy, Hyderabad, Telangana, 500108, India (069043)
FLUNINE (flunixin meglumine injection)
Original approval as a generic copy of NADA 101-479
522.970May 23, 2024
131-675
Intervet, Inc., 126 E Lincoln Ave., Rahway, NJ 07065 (000061)
SAFE-GUARD 20% (fenbendazole) Type A medicated article
Supplemental approval for the treatment and control of cecal worms (
                            *Aulonocephalus*
                             spp.) in wild quail
558.258June 4, 2024
138-255
Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215 (058005)
Iron Dextran 20% Injection (iron hydrogenated dextran injection) Injectable Solution
Supplemental approval for the prevention or treatment of iron deficiency anemia in nursing piglets
522.1182June 11, 2024
200-787
ZyVet Animal Health, Inc., 73 Route 31N, Pennington, NJ 08534 (086117)
Phenylpropanolamine Hydrochloride Chewable Tablets
Original approval for the control of urinary incontinence due to urethral sphincter hypotonus in dogs as a generic copy of NADA 141-324
520.1760June 17, 2024
200-785
Felix Pharmaceuticals PVT Ltd., 25-28 North Wall Quay, Dublin 1, IRELAND
Maropitant Citrate Tablets (maropitant citrate)
Original approval as a generic copy of NADA 141-262
520.1315June 20, 2024
200-784
ZyVet Animal Health, Inc., 73 Route 31N, Pennington, NJ 08534 (086117)
Trimeprazine with prednisolone tablets
Original approval as a generic copy of NADA 012-437
520.2604
 II. Change of Sponsor Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140 has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200-582 for LONCOR 300 (florfenicol) Injectable Solution to Zoetis Inc, 333 Portage St., Kalamazoo, MI 49007. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect this action. III. Change of Sponsor Address Ivaoes Animal Health (drug labeler code 086064 in 21 CFR 510.600(c)) has informed FDA that it has changed its address to 2101 W Atlantic Blvd., Suite 108, Pompano Beach, FL 33069. The entries in § 510.600(c) are amended to reflect this action. IV. Technical Amendments FDA is making the following amendments to improve the accuracy and readability of the animal drug regulations. 21 CFR 510.600 is amended to revise the entries for Ivaoes Animal Health Inc. in the lists of sponsors of approved applications and to add entries for Warburton Technology Ltd.
                    ( print page 85425)
                21 CFR 516.1760 is being amended to provide for additional strengths of phenobarbital tablets.
                21 CFR 520.2130 is amended to revise body weights of dogs and cats for treatment with spinosad chewable tablets.
                21 CFR 520.2598 is being amended to reflect an additional strength trilostane capsule.
                21 CFR 522.772 is amended to revise specific parasite indications and to reflect the prescription marketing status of doramectin and levamisole injectable solution for use in cattle.
                21 CFR 522.970 is amended to reflect approved food-producing animal species for separate sponsor products.
                21 CFR 522.1696b is amended to revise the preslaughter withdrawal period for cattle administered a penicillin G procaine aqueous suspension.
                21 CFR 529.1004 is amended to reflect approved conditions of use for formalin in finfish.
                21 CFR 529.1150 is amended to reflect approved conditions of use for hydrogen peroxide in freshwater-reared salmonids.
                21 CFR 556.275 is amended by adding a tolerance for residues of fenbendazole in edible tissues of quail established as a consequence of the supplemental approval of fenbendazole medicated quail feed.
                21 CFR 556.530 is added to provide tolerances for residues of pradofloxacin in edible tissues of cattle and swine.
                21 CFR 558.261 is being amended to reflect incorporation levels of florfenicol in medicated feed for freshwater-reared salmonids.
                21 CFR 558.450 is being amended to provide inclusion rates for oxytetracycline in medicated feed for finfish. V. Legal Authority This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.360b(i)). Although deemed a rule pursuant to the FD&C Act, this document does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a “rule of particular applicability” and is not subject to the congressional review requirements in 5 U.S.C. 801-808. Likewise, this is not a rule subject to Executive Order 12866. List of Subjects 21 CFR Part 510 Administrative practice and procedure
Animal drugs
Labeling
Reporting and recordkeeping requirements 21 CFR Part 516 Administrative practice and procedure
Animal drugs
Confidential business information
Reporting and recordkeeping requirements 21 CFR Parts 520, 522, 524, and 529 Animal drugs 21 CFR Part 556 Animal drugs
Dairy products
Foods
Meat and meat products 21 CFR Part 558 Animal drugs
Animal feeds
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 516, 520, 522, 524, 529, 556, and 558 are amended as follows: PART 510—NEW ANIMAL DRUGS
 1.The authority citation for part 510 continues to read as follows: Authority:
                        21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. 2.In § 510.600(c): a.In the table in paragraph (c)(1), revise the entry for “Ivaoes Animal Health” and add in alphabetical order an entry for “Warburton Technology Ltd.”; and b.In the table in paragraph (c)(2), add an entry in numerical order for “066679” and revise the entry for “086064”. The revisions and additions read as follows: § 510.600
  
 (c) * * * (1) * * * Firm name and address
Drug labeler
                                     code*         *         *         *         *         *         *Ivaoes Animal Health, 2101 W Atlantic Blvd., Suite 108, Pompano Beach, FL 33069
086064*         *         *         *         *         *         *Warburton Technology Ltd., 36 Fitzwilliam Square, Dublin 2, Dublin, D02HX82, Ireland
066679*         *         *         *         *         *         *
 (2) * * * Drug labeler
                                     code
Firm name and address*         *         *         *         *         *         *066679
Warburton Technology Ltd., 36 Fitzwilliam Square, Dublin 2, Dublin, D02HX82, Ireland.*         *         *         *         *         *         *086064
Ivaoes Animal Health, 2101 W Atlantic Blvd., Suite 108, Pompano Beach, FL 33069.*         *         *         *         *         *         *
 PART 516—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES
 3.The authority citation for part 516 continues to read as follows: Authority:
                        21 U.S.C. 360ccc-1, 360ccc-2, 371. 4.In § 516.1760, revise paragraph (a) to read as follows: § 516.1760
  (a) 
                            *Specifications.*
                             Each tablet contains 15, 16.2, 30, 32.4, 60, 64.8, 97.2 or 100 milligrams (mg) phenobarbital.
 5.Add § 516.2475 to subpart E to read as follows: § 516.2475
  (a) 
                            *Specifications.*
                             Each milliliter of solution contains 0.2 milligrams (mg) torsemide. (b) 
                            *Sponsor.*
                             See No. 017030 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use in dogs*
                            —(1) 
                            *Amount.*
                             Administer orally once daily at a dose of 0.05 to 0.2 mg/lb (0.11 to 0.44 mg/kg) of bodyweight. (2) 
                            *Indications for use.*
                             For use as concurrent therapy with pimobendan, spironolactone, and an angiotensin converting enzyme (ACE) inhibitor for the management of pulmonary edema in dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD). (3) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.
 PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
 6.The authority citation for part 520 continues to read as follows: Authority:
                        21 U.S.C. 360b. 7.In § 520.100, revise paragraph (b)(2), and remove paragraph (b)(3) to read as follows: § 520.100
  
 (b) * * * (2) Nos. 051072 and 066104 for use of product described in paragraph (a)(1) of this section as in paragraph (d) of this section.
 8.In § 520.1315, revise paragraph (b) to read as follows: § 520.1315
  
 (b) 
                            *Sponsors.*
                             See Nos. 054771, 086101, and 086117 in § 510.600(c) of this chapter.
 9.In § 520.1760, revise paragraph (b) to read as follows: § 520.1760
  
 (b) 
                            *Sponsors.*
                             See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section: (1) Nos. 055246 and 086117 for use of product described in paragraph (a)(1) of this section as in paragraphs (c)(1)(i) and (c)(2) and (3) of this section. (2) No. 055246 for use of product described in paragraph (a)(2) of this section as in paragraph (c)(1)(ii) and (c)(2) and)(3) of this section.
 10.In § 520.1780, revise paragraph (b) to read as follows: § 520.1780
  
 (b) 
                            *Sponsors.*
                             See Nos. 000010 and 069043 in § 510.600(c) of this chapter.
 § 520.2130
 11.In § 520.2130: a.In paragraph (d)(1)(ii), remove the text “3.3 pounds” and in its place add the text “5.0 pounds”; and b.In paragraph (d)(2)(ii), remove the text “2 pounds” and in its place add the text “4.1 pounds”. 12.In § 520.2598, revise paragraph (a) to read as follows: § 520.2598
  (a) 
                            *Specifications.*
                             Each capsule contains 5, 10, 20, 30, 60, or 120 milligrams (mg) trilostane.
 13.In § 520.2604, revise paragraph (b) to read as follows: § 520.2604
  
 (b) 
                            *Sponsors.*
                             See Nos. 054771 and 086117 in § 510.600(c) of this chapter.
 PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
 14.The authority citation for part 522 continues to read as follows: Authority:
                        21 U.S.C. 360b. 15.In § 522.304, revise paragraph (b) to read as follows: § 522.304
  
 (b) 
                            *Sponsors.*
                             See Nos. 016729, 017033, 054771, 055529, 069043, and 086101 in § 510.600(c) of this chapter.
 16.In § 522.772: a.Revise paragraph (d)(1)(ii); and b.In paragraph (d)(1)(iii), add a sentence to the end of the paragraph. The revision and addition read as follows: § 522.772
  
 (d) * * * (1) * * * (ii) 
                            *Indications for use.*
                             For treatment and control of gastrointestinal roundworms (adults and fourth stage larvae): 
                            *Ostertagia ostertagi*
                             (including inhibited larvae), 
                            *O. lyrata, Haemonchus placei,**Trichostrongylus axei, T. colubriformis,**T. longispicularis*
                             (adults only), 
                            *Oncophora, Cooperia pectinata*
                             (adults only), 
                            *C. punctata, C. surnabada,**Bunostomum phlebotomum*
                             (adults only), 
                            *Strongyloides papillosus*
                             (adults only), 
                            *Oesophagostomum radiatum, Trichuris*
                             spp. (adults only) and 
                            *Nematodirus helvetianus*
                             (adults only); lungworms (adults and fourth stage larvae): 
                            *Dictyocaulus viviparus;*
                             eyeworms (adults): 
                            *Thelazia*
                             spp.; grubs (parasitic stages): 
                            *Hypoderma bovis*
                             and 
                            *H. lineatum;*
                             sucking lice: 
                            *Haematopinus eurysternus, Linognathus vituli,*
                             and 
                            *Solenopotes capillatus;*
                             mange mites: 
                            *Psoroptes bovis*
                             and 
                            *Sarcoptes scabiei*
                             in beef cattle 2 months of age and older and replacement dairy heifers less than 20 months of age. Not for use in beef bulls intended for breeding over 1 year of age, dairy calves, and veal calves. (iii) * * * Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 § 522.955
 17.In § 522.955: a.In paragraph (b)(3), remove the text “Nos. 058005, 058198, and 069043” and in its place add the text “Nos. 054771, 058005, and 069043”; and b.In paragraph (d)(1)(ii)(C), in the second sentence, remove the text “Nos. 000061, 058005, 058198, and 069043” and in its place add the text “Nos. 000061, 054771, 058005, and 069043”. 18.In § 522.970, revise paragraphs (b)(1) and (3) to read as follows: § 522.970
  
 (b) * * * (1) See Nos. 000061, 055529, and 061133 for use as in paragraph (e) of this section. 
 
 
 (3) See Nos. 016592, 058198, and 069043 for use as in paragraphs (e)(1) and (2) of this section.
 19.In § 522.1182, revise introductory text of paragraph (b)(7) to read as follows: § 522.1182
  
 (b) * * * (7) Nos. 016592, 042552, and 058005 for use product described in paragraph (a)(2) of this section as follows:
 20.In § 522.1696b, revise paragraph (d)(2)(iii)(B) to read as follows: § 522.1696b
  
 (d) * * * (2) * * * (iii) * * * (B) For Nos. 016592 and 055529: treatment should not exceed 4 consecutive days. A withdrawal period has not been established for this product in pre-ruminating calves. Discontinue treatment for the following number of days before slaughter: cattle—14; sheep—9; and swine—7.
 21.Add § 522.1860 to read as follows: § 522.1860
  (a) 
                            *Specifications.*
                             Each milliliter (mL) of solution contains 200 milligrams (mg) pradofloxacin. (b) 
                            *Sponsor.*
                             See No. 058198 in § 510.600(c) of this chapter. (c) 
                            *Related tolerances.*
                             See § 556.530 of this chapter. (d) 
                            *Conditions of use*
                            —(1) 
                            *Cattle—*
                            (i) 
                            *Amount.*
                             Administer a single dose of 10 mg/kg (2.3 mL/100 lb) body weight by subcutaneous injection. (ii) 
                            *Indications for use.*
                             Cattle intended for slaughter (beef calves 2 months of age and older, growing beef steers, growing beef heifers, and beef bulls intended for slaughter), and in cattle intended for breeding less than 1 year of age (replacement beef and dairy heifers less than 1 year of age and beef and dairy bulls less than 1 year of age): for the treatment of bovine respiratory disease associated with 
                            *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni,*
                             and 
                            *Mycoplasma bovis.* (iii) 
                            *Limitations.*
                             Cattle intended for human consumption must not be slaughtered within 4 days of treatment. Not for use in female dairy cattle 1 year of age and older, including dry dairy cows; use in these cattle may cause drug residues in milk and/or in calves born to these cows. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals. (2) 
                            *Swine—*
                            (i) 
                            *Amount.*
                             Administer a single dose of 7.5 mg/kg (1.7 mL/100 lb) body weight by intramuscular injection. (ii) 
                            *Indications for use.*
                             Weaned swine intended for slaughter (nursery, growing, and finishing swine, boars intended for slaughter, barrows, gilts intended for slaughter, and sows intended for slaughter): for the treatment of swine respiratory disease associated with 
                            *Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, Streptococcus suis,*
                             and 
                            *Mycoplasma hyopneumoniae.* (iii) 
                            *Limitations.*
                             Swine intended for human consumption must not be slaughtered within 2 days of treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.
 22.In § 522.2478: a.Redesignate paragraphs (a)(1)(i) and (ii) as paragraphs (a)(1)(ii) and (iii); b.Add new paragraph (a)(1)(i); c.Revise paragraphs (d)(1)(i)(A), (B), and (D); and d.Add paragraph (d)(3). The revisions and additions read as follows: § 522.2478
  (a) * * * (1) * * * (i) 50 milligrams (mg) trenbolone acetate and 7 mg estradiol benzoate (one implant consisting of two pellets, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate) per implant dose. 
 (d) * * * (1) * * * (i) * * * (A) An implant containing 100 mg trenbolone acetate and 14 mg estradiol benzoate as described in paragraph (a)(1)(ii) of this section for increased rate of weight gain in growing beef steers fed in confinement for slaughter and for increased rate of weight gain and improved feed efficiency in growing beef heifers fed in confinement for slaughter. For increased rate of weight gain for up to 200 days in a reimplantation program where an implant as described in paragraph (a)(1)(ii) of this section is the first implant and an implant as described in paragraph (a)(1)(ii) or (iii) or (a)(2)(ii) of this section is administered 60 to 120 days later. (B) An implant containing 200 mg trenbolone acetate and 28 mg estradiol benzoate as described in paragraph (a)(1)(iii) of this section for increased rate of weight gain and improved feed efficiency in growing beef steers fed in confinement for slaughter and for increased rate of weight gain in growing beef heifers fed in confinement for slaughter. For increased rate of weight gain for up to 200 days in a reimplantation program where an implant as described in paragraph (a)(1)(ii) of this section is the first implant and an implant as described in paragraph (a)(1)(iii) of this section is administered 60 to 120 days later. 
 (D) An extended-release implant containing 200 mg trenbolone acetate and 28 mg estradiol benzoate as described in paragraph (a)(2)(ii) of this section for increased rate of weight gain and improved feed efficiency for up to 200 days. For increased rate of weight gain for up to 200 days in a reimplantation program where an implant as described in paragraph (a)(1)(ii) of this section is the first implant and an implant as described in paragraph (a)(2)(ii) of this section is administered 60 to 120 days later. 
 (3) 
                            *Growing beef steers and heifers in a dry lot*
                            —(i) 
                            *Amount and indications for use.*
                             (A) An implant containing 50 mg trenbolone acetate and 7 mg estradiol benzoate as described in paragraph (a)(1)(i) of this section for increased rate of weight gain in growing beef steers and heifers in a dry lot. (B) An implant containing 100 mg trenbolone acetate and 14 mg estradiol benzoate as described in paragraph (a)(1)(ii) of this section for increased rate of weight gain in growing beef steers and heifers in a dry lot. (ii) 
                            *Limitations.*
                             Implant pellets subcutaneously in ear only. Not approved for repeated implantation (reimplantation) with this or any other cattle ear implant in growing beef steers and heifers in a dry lot. Safety and effectiveness following reimplantation have not been evaluated. Do not use in beef calves less than 2 months of age, dairy calves, and veal calves because effectiveness and safety have not been established. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in dairy cows or in animals intended for subsequent breeding. Use in these cattle 
                            ( print page 85428)
                            may cause drug residues in milk and/or in calves born to these cows.
 23.Add § 522.2694 to read as follows: § 522.2694
  (a) 
                            *Specifications.*
                             Each milliliter (mL) of solution contains 60 milligrams (mg) zinc as zinc oxide, 15 mg copper as copper carbonate, 10 mg manganese as manganese carbonate, and 5 mg selenium as sodium selenite. (b) 
                            *Sponsor.*
                             See No. 066679 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use*
                            —(1) 
                            *Amount.*
                             Administer a single dose by subcutaneous injection to cattle up to 1 year of age, 1 mL/100 lb bodyweight; to cattle from 1 to 2 years of age, 1 mL/150 lb bodyweight, and to cattle over 2 years of age, 1 mL/200 lb bodyweight. (2) 
                            *Indications for use.*
                             As a supplemental source of zinc, copper, manganese, and selenium in cattle. (3) 
                            *Limitations.*
                             Cattle must not be slaughtered for human food consumption within 14 days of the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
 24.The authority citation for part 524 continues to read as follows: Authority:
                        21 U.S.C. 360b. 25.In § 524.802, revise paragraph (b) to read as follows: § 524.802
  
 (b) 
                            *Sponsors.*
                             See Nos. 058198 and 069043 in § 510.600(c) of this chapter.
 PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS
 26.The authority citation for part 529 continues to read as follows: Authority:
                        21 U.S.C. 360b. 27.In § 529.1004, in the table in paragraph (d)(2)(ii), revise footnote 1 to read as follows: § 529.1004
  
 (d) * * * (2) * * * (ii) * * * Aquatic species
Administer in tanks and raceways for up to 1 hour
                                     (microliter/liter or part per million 
                                     (μL/L or ppm))
Administer in earthen ponds single treatment
                                     (μL/L or ppm)*         *         *         *         *         *         *1
                                 Use the lower concentration when ponds are heavily loaded with phytoplankton or fish to avoid oxygen depletion due to the biological oxygen demand by decay of dead phytoplankton. Alternatively, a higher concentration may be used if dissolved oxygen is strictly monitored.
 28.In § 529.1150, revise paragraph (c)(1)(iv) to read as follows: § 529.1150
  
 (c) * * * (1) * * * (iv) Freshwater-reared salmonids for the treatment and control of 
                            *Gyrodactylus*
                             spp: 100 mg/L for 30 minutes, or 50 mg/L for 60 minutes, in a continuous flow water supply or as a static bath once per day on alternate days for three treatments.
 PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
 29.The authority citation for part 556 continues to read as follows: Authority:
                        21 U.S.C. 342, 360b, 371. 30.In § 556.275, add paragraph (b)(6) to read as follows: § 556.275
  
 (b) * * * (6) 
                            *Quail.*
                             (i) Liver (target tissue): 6 ppm fenbendazole sulfone (marker residue). (ii) [Reserved]
 31.Add § 556.530 to subpart B to read as follows: § 556.530
  (a) 
                            *Acceptable daily intake (ADI).*
                             The ADI for total residue of pradofloxacin is 2 μg/kg of body weight per day. (b) 
                            *Tolerances.*
                             The tolerances for pradofloxacin (marker residue) are: (1) 
                            *Cattle.*
                             Kidney (target tissue): 30 ppb. (2) 
                            *Swine.*
                             Kidney (target tissue): 1 ppm. (c) 
                            *Related conditions of use.*
                             See § 522.1860 of this chapter.
 PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
 32.The authority citation for part 558 continues to read as follows: Authority:
                        21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371. 32.In § 558.258, add heading to paragraph (e)(1) and add paragraph (e)(5)(iv) to read as follows: § 558.258
  
 (e) * * * (1) 
                            *Turkeys.* 
 (5) * * * Species/class
Fenbendazole
                                     grams per ton
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(iv) Wild quail
90.7
For the treatment and control of Gastrointestinal worms: cecal worms (
                                    *Aulonocephalus*
                                     spp.)
Feed for 21 consecutive days. Prior withdrawal of feed is not necessary
000061
 33.In § 558.261, revise paragraph (e)(2)(ii) to read as follows: § 558.261
  
 (e) * * * (2) * * *
                            ( print page 85429) Florfenicol in grams/ton of feed
Indications for use
Limitations*         *         *         *         *         *         *(ii) 182 to 2,724
Freshwater-reared salmonids: for the control of mortality due to coldwater disease associated with 
                                    *Flavobacterium psychrophilum*
                                     and furunculosis associated with 
                                    *Aeromonas salmonicida*
Feed as a sole ration for 10 consecutive days to deliver 10 to 15 mg florfenicol per kg of fish. Feed containing florfenicol shall not be fed for more than 10 days. Following administration, fish should be reevaluated by a licensed veterinarian before initiating a further course of therapy. The effects of florfenicol on reproductive performance have not been determined. Feeds containing florfenicol must be withdrawn 15 days prior to slaughter.*         *         *         *         *         *         *
 34.In § 558.450, revise paragraphs (e)(5)(iv), (v), and (vi) to read as follows: § 558.450
  
 (5) * * * Oxytetracycline amount
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(iv) 333 to 7,500 g/ton to provide 2.5 to 3.75 g/100 lb of fish/day
1. Freshwater-reared salmonids: for control of ulcer disease caused by 
                                    *Haemophilus piscium,*
                                     furunculosis caused by 
                                    *Aeromonas salmonicida,*
                                     bacterial hemorrhagic septicemia caused by 
                                    *A. hydrophila,*
                                     and pseudomonas disease
Administer in mixed ration for 10 days. Do not liberate fish or slaughter fish for food for 21 days following the last administration of medicated feed
0661042. Catfish: for control of bacterial hemorrhagic septicemia caused by 
                                    *A. hydrophila*
                                     and pseudomonas disease
Administer in mixed ration for 10 days. Do not liberate fish or slaughter fish for food for 21 days following the last administration of medicated feed. Do not administer when water temperature is below 16.7 °C (62 °F)
066104(v) 500 to 7,500 g/ton to provide 3.75 g/100 lb of fish/day
1. Freshwater-reared salmonids: for control of mortality due to coldwater disease associated with 
                                    *Flavobacterium psychrophilum*
                                     or for control of mortality due to columnaris disease associated with 
                                    *Flavobacterium columnare*
Administer in mixed ration for 10 days. Do not liberate fish or slaughter fish for food for 21 days following the last administration of medicated feed
0661042. Freshwater-reared salmonids weighing up to 55 grams: for marking of the skeletal tissue
Feed for 10 days. Immediate release is permitted following last feeding of medicated feed
0661043. Catfish: for control of mortality due to columnaris disease associated with 
                                    *Flavobacterium columnare*
Administer in mixed ration for 10 days. Do not liberate fish or slaughter fish for food for 21 days following the last administration of medicated feed. Do not administer when water temperature is below 16.7 °C (62 °F)
066104(vi) 1.25 to 25 g/kg to provide 11.35 g/100 lb of fish/day
Pacific salmon not over 30 grams body weight: for marking of the skeletal tissue
Administer medicated feed as the sole ration for 4 consecutive days. Do not liberate for at least 7 days following last feeding of medicated feed
066104*         *         *         *         *         *         *
 Dated: October 21, 2024. Eric Flamm, Acting Associate Commissioner for Policy.


[FR Doc. 2024-24820 Filed 10-25-24; 8:45 am] BILLING CODE 4164-01-P